Author of

• 20167

  +

  P2.03 - Chemotherapy/Targeted Therapy (ID 704)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Chemotherapy/Targeted Therapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 23309

    +

    P2.03-038 - Early Serum Tumor Markers After 14 Days of Tyrosine Kinase Inhibitor Target Therapy Predicts Outcomes in Patients with Lung Adenocarcinoma (ID 9432)

    09:30 - 16:00  |  Presenting Author(s): Kuo-Yang Huang
    • Abstract
    • Slides

    Background:
    The aim of the study was to demonstrate whether early variations in the levels of serum 4 tumor markers (TMs), carcinoembryonic antigen [CEA], cancer antigen [CA]125, CA19-9, and CA15-3), after TKI target therapy were associated with treatment response and progression-free survival (PFS) in patients with lung adenocarcinoma.
    
    Method:
    Patients with stage IIIB-IV lung adenocarcinoma taking epidermal growth factor receptor (EGFR) TKIs or anaplastic lymphoma kinase (ALK) inhibitors were enrolled prospectively from June 2012 to February 2015. According to the variations of percentage of change in 4-TM levels (4-TM~pc~), we divided patients into ascending (increases in 4-TM~pc~ over the 7[th]- 14[th ]day) and descending (decreases in 4-TM~pc~ over the 7[th]- 14[th ]day) groups.
    
    Result:
    In all, 184 patients were enrolled, and 89% had at least one of the pre-treatment evaluable TMs and were further analyzed. A good response to the TKI target therapy was accurately predicted in the descending group, as determined using receiver operating characteristic curve analysis (an area under the curve, 0.83). The kappa value between type of 4-TM~pc~ and measurable radiographic lesions was 0.762. Multivariate Cox hazards model analyses demonstrated that the type of 4-TM~pc~ and mutation status were the strongest predictors of PFS (descending versus ascending, hazard ratios [HR] 0.30, 95% confidence interval [CI], 0.19–0.47; sensitive mutation versus wide type, HR 0.30, 95% CI, 0.19–0.48).
    
    Conclusion:
    Type of 4-TM~pc~ 14 days after TKI target therapy is associated with an image response and PFS, without regarding mutation status, in patients with advanced lung adenocarcinoma.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.